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Background: Mercaptopurine (6-MP) plays a pivotal role in treatment of childhood acute lymphoblastic leukemia
(ALL); however, interindividual variability in toxicity of this drug due to genetic polymorphism in 6-MP metabolizing
enzymes has been described. We determined the prevalence of the major genetic polymorphisms in 6-MP
metabolizing enzymes in Chilean children with ALL.
Methods: 103 Chilean pediatric patients with a confirmed diagnosis of ALL were enrolled. DNA was isolated from
whole blood and genetic polymorphism in thiopurine S-methyltransferase (TPMT) and inosine triphosphate
pyrophosphatase (ITPA) coding genes were detected by polymorphism chain reaction-restriction fragment length
(PCR-RFLP) assay.
Results: The total frequency of variant TPMT alleles was 8%. TPMT*2, TPMT*3A and TPMT*3B alleles were found in
0%, 7%, and 1% of patients, respectively. For ITPA, the frequency of P32T allele was 3%. We did not observe any
homozygous variant for TPMT and ITPA alleles. We also analyzed a subgroup of 40 patients who completed the
maintenance phase of ALL treatment, and we found that patients carrying a TPMT gene variant allele required a
significantly lower median cumulative dosage and median daily dosage of 6-MP than patients carrying wild type
alleles.
Conclusion: TMPT genotyping appears an important tool to further optimize 6-MP treatment design in Chilean
patients with ALL.
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Mercaptopurine (6-MP) is a highly effective chemo-
therapeutic agent for the treatment of childhood acute
lymphoblastic leukemia (ALL), and is extensively used
in therapeutic protocols worldwide [1]. Hematological
and hepatic toxicities are the most common adverse
effects associated with cumulative toxic plasma con-
centrations of 6-MP metabolites [2,3]. Pharmamacoge-
netics has provided a molecular approach to guide the* Correspondence: mfarfan@med.uchile.cl
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reproduction in any medium, provided the orindividualization of cancer chemotherapy, reducing
toxicity and increasing safety of the therapy [4]. Phar-
macogenetic studies in childhood ALL have associated
toxicity to 6-MP to single nucleotide polymorphism
(SNP) in genes coding for 6-MP metabolizing enzymes
such as thiopurine S-methyltransferase (TPMT) and
inosine triphosphate pyrophosphatase (ITPA) [5,6].
TPMT is a cytosolic enzyme that catalyses the methyla-
tion of aromatic and heterocyclic sufohydroxyl groups in
6-MP and their nucleotide metabolites [7]. TPMT exhibits
genetic polymorphism in all large ethnic groups, including
Caucasians, Africans, African-Americans, and Asians and
has been associated with high levels of 6-MP metabolitestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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monogenic co-dominant inheritance. Approximately
one in 300 persons inherit two variant TPMT alleles and
are TPMT deficient, and about 5%-10% are heterozygotes
with intermediate enzyme activity, leading to severe
and moderate to severe myelosuppression when pa-
tients are treated with conventional doses [6]. To date,
more than 20 SNPs for TPMT have been described,
but alleles TPMT*2 (1800462), TPMT*3A (rs1800460),
and TPMT*3C (rs1142345) comprise about 80-95% of
all variant alleles described so far [1-3].
ITPA is another enzyme involved in 6-MP metabolism.
This enzyme catalyzes the hydrolysis of inosine triphos-
phate (ITP) to inosine monophosphate (IMP), protect-
ing cells from the accumulation of harmful nucleotides
such as ITP and deoxyinosine triphosphate. A C198A
transversion (rs1127354) causing a Proline to Threonine
replacement at codon 32 (P32T polymorphism) is the
most relevant SNP determining low ITPA enzymatic
activity [5,9].
The knowledge of SNP in 6-MP metabolizing enzymes
and its related drug toxicity has developed more rational
approaches to optimize chemotherapy in patients with
ALL. Genetic variants for TPMT and ITPA differ from
patient to patient and among different ethnic groups and
impact individual toxicity related to 6-MP. Determination
of the frequency of these genetic variants is necessary
when considering the use of pharmacogenetics as a tool to
improve treatment outcome. In this study, we determined
the prevalence of TPMT and ITPA polymorphisms in
Chilean children with ALL to help better characterize
patients from Latin America because at our institution
we are increasingly employing pharmacogenetic data for
the design of new treatment strategies. In addition, we




In a prospective study, between June 2009 and March 2010
we collected blood samples from 103 new patients under
18 years of age with a confirmed diagnosis of ALL, treated
at the Dr. Luis Calvo Mackenna Hospital (n = 89) in
Santiago, Chile, and Dr. Gustavo Fricke Hospital (n = 14) in
Viña del Mar, Chile. These hospitals are members of the
BFM international consortium for the treatment of child-
hood ALL, so patients were enrolled in ALL-IC-BFM2002,
the therapeutic protocol open during the study period. As
maintenance therapy, all patients received oral 6-MP
50 mg/m2 daily, and methotrexate (MTX) 15 mg/m2
weekly; both were taken in the evening on an empty stom-
ach without milk. At the time of blood collection for the
polymorphism study, all patients and/or parents provided
written informed consent to participate in the study,approved by the Ethical Committee of the Dr. Luis Calvo
Mackenna Hospital and Dr. Gustavo Fricke Hospital.
DNA extraction
We collected peripheral blood samples (2–4 mL) from
study participants in tubes containing sodium EDTA. A
unique accession number to each sample was assigned
and DNA from 200 μL of total blood was extracted by
using the QIAmp DNA blood kit (Qiagen Inc., Valencia,
CA). DNA was diluted in 200 μL distilled water and stored
at −20°C until analysis.
Genotyping
PCR-RFLP analyses were used to evaluate genetic poly-
morphism in TPMT (TPMT*2, TPMT*3A, TPMT*3B
and TPMT*3C), ITPA (P32T) using methods previously
described [5,10].
TPMT activity measurement
Erythrocyte TPMT activity was measured by use of blood
collected in heparinized tubes, as previously described
[11]. Briefly, erythrocytes were washed with 0.9% NaCl
and lysed with cold water. Erythrocyte membranes were
then separated by centrifugation for 10 minutes at 12,000 × g.
The lysates were stored at −80°C until analyzed. TPMT
activity was normalized per milliliter of packed red
blood cells (Units/mL). Erythrocyte TPMT activity was
measured 30 or more days following the last erythrocyte
transfusion. TPMT activity measurement was performed
at The Department of Pharmaceutical Sciences, St. Jude
Children’s Research Hospital (Memphis, TN) through
collaboration with Dr. Mary V. Relling and co-workers.
6-MP dosages and laboratory data collection
The mean daily and cumulative dosages of 6-MP (in mg/
m2/day and mg/m2) were calculated for the patients carry-
ing variant and wild type alleles. Hematologic and hepatic
laboratory parameters related with 6-MP toxicity were
monitored every two weeks during the follow-up mainten-
ance period and obtained from clinical charts and labora-
tory databases. The mean value for each test was also
calculated. The documented tests were leucocytes, plate-
let, percentage of neutrophils, absolute neutrophils count
(ANC), Aspartate Transaminase (AST), Alanine Trans-
aminase (ALT) and total and direct bilirubin.
Data analysis
All data were entered into an electronic database and
analyzed by the χ2 test. GraphPad Prism software ver-
sion 3.0 (GraphPad Software, San Diego, CA) was used
for all calculations. The Wilcoxon rank sum test and
95% confidence interval for differences between median
values were used to compare TPMT activities between
subpopulations and the Mann–Whitney Rank Sum Test
Figure 1 Erythrocyte TPMT activity in Chilean patients with
ALL. TPMT enzyme activity from packed red blood cells (PRBC) in
patients with a TPMT variant allele (WT/Mut; n = 6) compared to the
activity identified in patients without the variant present (WT/WT;
n = 7). The Wilcoxon rank sum test and 95% confidence interval for
differences between median values were used to compare TPMT
activities between subpopulations. P values ≤0.05 were considered
statistically significant.
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with the two genotypes for continuous variables or param-
eters. In all tests P values ≤0.05 were considered statisti-
cally significant.
Results
Prevalence of TPMT and ITPA genetic polymorphisms in
ALL patients
We enrolled 103 patients newly diagnosed with childhood
ALL having a mean age of 8.7 years; 42/103 (41%) were
male. TPMT and ITPA genetic polymorphisms were
found in 8/103 (8%) and 3/103 (3%) patients, respectively.
For TPMT, TPMT*3A and TPMT*3C polymorphisms
were found in 7/103 (7%) and 1/103 (1%) patients, re-
spectively. We found no homozygous variant for TPMT
and ITPA genes and no TPMT*2 and TPMT*3B alleles
(Table 1). To correlate these findings with the TPMT
phenotype, we assayed the TPMT enzyme activity from
blood erythrocytes in 6 randomly selected patients with a
variant allele in the TPMT gene. A significantly lower
TPMT activity was found in all patients with TPMT poly-
morphism compared to 7 patients lacking the inactivating
variant (Figure 1).
Association of TPMT and ITPA genetic polymorphisms
with 6-MP toxicity and dosage
To associate the presence of a TPMT and ITPA poly-
morphism with 6-MP toxicity and dosage, we analyzed
ALL patients who completed the maintenance phase.
The analysis of the subgroup of 40 ALL patients, showed
that 35/40 (88%) carried wild type alleles and 5/40 (12%)
carried a TPMT variant allele. No statistical differences
in the measured parameters between groups were seen
(Table 2). We also determined the median cumulative
dosage and median daily dosage of 6-MP in the same
group of patients and found that ALL patient carrying a
TPMT gene variant allele had a significantly lower median
cumulative dosage and median daily dosage of 6-MP com-
pared to patients carrying wild type alleles (Figure 2). NoTable 1 TPMT and ITPA genotype frequencies in 103
Chilean children with ALL
Genotype n = 103 %
TPMT
TPMT*1/ TPMT*1 95 92
TPMT*2/ TPMT*1 0 0
TPMT*3A/ TPMT*1 7 7
TPMT*3B/ TPMT*1 0 0
TPMT*3C/ TPMT*1 1 1
ITPA
ITPA 94 C/C 100 97
ITPA 94 C/A 3 3differences in 6-MP toxicity or dosage were associated
with ITPA polymorphisms (data not shown).
Discussion
The latest clinical guidelines for the Childhood LLA
(LLA-IC-BFM 2002) note that TPMT is a gene related
to the antileukemic effect and side effects of 6-MP and
that it is mentioned as a potential gene selected for poly-
morphism testing [12]. We conducted this study because
of the increasing interest at our institutions in employing
pharmacogenetics to refine and better individualize treat-
ment for childhood leukemia. Although this study con-
firmed previous reports about the high concordance
between TPMT genotype and phenotype, it is important
to demonstrate these observations in our population, if
we were to consider TPMT genotyping as a diagnostic
tool to predict TPMT activity and its potential to de-
velop toxicity to 6-MP at the standard dosage.
Differences in TPMT polymorphisms vary among
ethnic groups, ranging from 2% to 14% prevalence. We
found that allelic frequency of the most relevant TPMT
polymorphisms in Chilean patients with ALL was 8%
(Table 1), similar to that found in Chilean blood donors
from a previous study [13], although we did not find the
TPMT*2 allele. The frequency and distribution of TPMT
alleles in Chile are similar to that of Hispanics in other
Latin American countries. In fact, within the region, poly-
morphism prevalence differs only in Brazil [14,15], a find-
ing explained by their unique racial mixture.
One of the major aspects about pharmacogenetics is
the clinical consequences of one particular polymorph-
ism in the treatment outcome. Several studies indicate
that TPMT polymorphisms are associated with 6-MP
Table 2 Demographic profile, laboratory parameters and
drug dosages during maintenance therapy of ALL
children studied with and without TPMT polymorphisms







14 (11.5-20.5) 14 (12–16) 0.782
Leucocytes (×109/L) 2.7 (2.35-4.23) 3.2 (2.56-4.14) 0.597
Platelet (×109/L) 265.4 (±105.8) 227.7 (±70.3) 0.286
Percentage of neutrophils 56.4 (±14.5) 55.5 (±12.9) 0.887
ANC (×109/L) 1.35 (1.08-2.68) 1.84 (1.30-2.20) 0.438
AST (mg/dL) 35.0 (33.7-47.5) 46.5 (30.5-54.0) 0.528
ALT (mg/dL) 28.5 (17.5-69.0) 61.0 (22.0-84.5) 0.159
Total Bilirubin (mg/dL) 0.43 (0.35-0.7) 0.59 (0.51-0.78) 0.141




Figure 2 TPMT polymorphism and 6-MP dosage in Chilean
children with ALL. Cumulative dosage (A) and daily dosage (B) of
6-MP between patients carrying a TPMT gene variant allele
compared to patients carrying wild type alleles. The Mann–Whitney
Rank Sum Test was used to compare 6-MP dosage between both
groups. P values ≤0.05 were considered statistically significant.
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with clinical findings we determined laboratory parame-
ters and 6-MP dosage in ALL patients who completed the
maintenance phase of the ALL treatment. The median
daily and cumulative dosages of 6-MP in the maintenance
phase were significantly lower in patients carrying variant
alleles compared to wild type patients (Figure 2). These
observations are in agreement with previous reports [18].
However, we did not find statistical differences in labora-
tory parameters related to drug toxicities, a situation that
might be explained by 6-MP dosage adjustment using
ANC values as clinical guidelines suggest. Overall, these
observations strongly support the importance of TPMT
genotyping, identifying high risk patients that can be
treated with reduced dosages of 6-MP without comprom-
ising the ALL treatment.
ITPA is another enzyme involved in the 6-MP metab-
olism. Genetic polymorphisms in the ITPA gene are
associated with reduced activity of the ITPA enzyme
and increased toxicity to mercaptopurine. Several poly-
morphisms have been described for ITPA, but the P32T
variant is the most common SNP [5]. The distribution
of P32T polymorphism varies from 1% to 15%. In this
study, we found that the prevalence of ITPA was 1% in
ALL patients (Table 1), which is in agreement with the
frequency reported within other Hispanic groups [19].
However, we did not find differences in 6-MP toxicity
or dosage in patients carrying the P32T polymorphism
compared to wild type patients, a situation might be ex-
plained by the low the prevalence for ITPA found in this
study. A recent study supports the importance of this
polymorphism when 6-MP dosages had been adjusted
for TPMT genotype [20]. Therefore, prospective studies
analyzing the involvement of TPMT and ITPA poly-
morphism and adverse reaction to 6-MP are warranted.
Conclusion
We report the prevalence of the major polymorphisms
in 6-MP metabolizing enzymes in Chilean patients with
childhood ALL. Our data strongly support the importance
of TPMT genotyping in patients with ALL to design better
and more rational treatment strategies using 6-MP in chil-
dren with ALL.
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